Zhongguancun (000931.SZ) subsidiary company has obtained a drug registration certificate for Hydrocone Hydrochloride Sustained-Release Tablets.

Zhito Finance APP reported that Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. (referred to as: Beijing Huasu) has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration, confirming that the "Oxycodone Hydrochloride Extended-Release Tablets" (Specification: 40mg) developed by Beijing Huasu has passed the drug registration review and approval.